The AMDHD2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product features targeted disruption of the AMDHD2 gene, which encodes imidazolone-5-propanoate hydrolase, a key enzyme in the histidine catabolic pathway. The polyclonal nature of this knockout pool provides a heterogeneous population of cells with a spectrum of mutations at the target locus, facilitating robust loss-of-function studies without the need for single-cell cloning. This format is particularly suited for investigating gene function in a physiologically relevant epithelial context and can serve as a versatile platform for both mechanistic and translational research.
The parental A-549 cell line was originally derived from the alveolar basal epithelial cells of a 58-year-old male patient with lung adenocarcinoma. As an epithelial type II pneumocyte model, A-549 cells retain many features of alveolar epithelium, including the ability to form monolayers and express characteristic epithelial markers. This cell line is widely employed in cancer biology, drug metabolism, and respiratory disease research due to its well-characterized signaling networks and responsiveness to genetic manipulation. Its tumorigenic origin makes it an appropriate system to study metabolic adaptations in lung cancer, particularly in the context of amino acid catabolism pathways such as histidine degradation.
AMDHD2 catalyzes the hydrolysis of imidazolone-5-propanoate to formiminoglutamate, a critical step in the conversion of histidine to glutamate. Within the histidine degradation pathway, AMDHD2 operates downstream of histidine ammonia-lyase (HAL), which deaminates histidine to urocanate, and urocanate hydratase (UROC1), which hydrates urocanate to imidazolone-5-propanoate. The product formiminoglutamate is subsequently processed by formiminotransferase cyclodeaminase (FTCD) to yield glutamate and one-carbon tetrahydrofolate derivatives. Disruption of AMDHD2 is expected to impair flux through this pathway, leading to accumulation of upstream metabolites and potential redirection of carbon and nitrogen metabolism. While direct upstream regulators of AMDHD2 transcription have not been fully elucidated, its activity is inherently linked to histidine availability and the metabolic state of the cell. In cancer cells such as A-549, alterations in amino acid catabolism can influence anabolic pathways, redox balance, and epigenetic regulation, highlighting the significance of AMDHD2 in maintaining metabolic homeostasis.
In the A-549 lung adenocarcinoma background, AMDHD2 knockout provides a unique tool to probe the role of histidine catabolism in cancer cell metabolism. Lung adenocarcinoma cells often exhibit reprogrammed nutrient utilization to support proliferation and survival under various microenvironmental conditions. By ablating AMDHD2 function, researchers can investigate how histidine pathway intermediates may modulate cellular energetics, one-carbon metabolism, and the response to therapeutic agents. This knockout model may also reveal vulnerabilities in histidine-dependent processes, potentially uncovering new targets for metabolic intervention in lung cancer. The polyclonal pool allows assessment of the overall biological consequence of gene disruption while minimizing clone-specific artifacts, making it suitable for bulk assays such as metabolomics and proliferation studies.
This product is ideally suited for a range of applications including functional studies of histidine metabolism, investigation of metabolic reprogramming in lung adenocarcinoma, and enzymological characterization of the amidohydrolase family. The polyclonal knockout cells can be used in comparative metabolomics by LC-MS to profile histidine-related metabolites, in Western blotting and RT-qPCR to confirm loss of AMDHD2 expression, and in Sanger sequencing-based indel analysis to verify target-locus editing. Cell proliferation assays can assess the impact of AMDHD2 disruption on growth under varied nutrient conditions. These cells may also serve as a platform for screening small-molecule modulators of histidine catabolism or for evaluating the interplay between amino acid degradation pathways and oncogenic signaling. For further technical details or batch-specific validation data, please contact Ascent Research.
